<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188912</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005155</org_study_id>
    <secondary_id>NCI-2019-07293</secondary_id>
    <secondary_id>10134</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>U01CA236229</secondary_id>
    <nct_id>NCT04188912</nct_id>
  </id_info>
  <brief_title>Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study</brief_title>
  <acronym>CATCH</acronym>
  <official_title>Close Assessment and Testing for Chronic GVHD (The CATCH Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial observes and collects samples from patients before and after stem cell
      transplantation to learn more about how and why a complication called chronic
      graft-versus-host disease (GVHD) develops after stem cell transplantation. Performing close
      observation and various types of testing may enable doctors to notice symptoms or problems
      sooner than they would normally have been noticed and predict which patients will develop
      chronic GVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:

      Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem
      cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD
      onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2,
      2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may
      undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12
      months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of
      the eyes, mouth and skin, and optical coherence tomographybefore stem cell transplant, at
      2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients
      without standard of care formal pulmonary function test undergo portable spirometry at 2-3,
      4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also
      complete surveys and have their medical records reviewed.

      After completion of study, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of cytokines</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will compare the pg/ml levels and trajectories of proteins (IL-1b; IL-4; IL-5; IL-6; IL-8; IL-10; IL-13; IL-17a (pg/mL); TNF; G-CSF; IFNgamma; MCP-1; IL-12p40; GM-CSF; IL-2) between patients who do and do not develop chronic graft versus host disease (cGVHD). Blood will be analyzed separately from saliva and conjunctival washings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of cGVHD</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Onset of cGVHD will be treated as a time-to-event endpoint, using Cox regression with monthly levels or slopes of the markers entered as time dependent covariates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of cellular populations</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will compare the levels, proportions and trajectories of different cellular populations between those with and without cGVHD, and with different cGVHD organ involvement and symptoms. The following cell subtypes are of highest interest: Th17, FOXP3+ T regulatory cells, FOXP3- T regulatory type 1 (TR1) cells, T follicular helper cells, activated B cells, B regulatory cells, and monocytes but the list may evolve before actual testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with tissue alterations in skin, mouth and eyes</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Tissue alterations will be classified into Abnormal and Normal, and measured by biopsy and/or advanced bioimaging techniques. Histologic findings, ribonucleic acid (RNA) expression profiles, optical coherence tomography (OCT) findings and digital image interpretations will be compared between patients who do and do not develop cGVHD or who have different cGVHD clinical phenotypes and symptoms.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
    <description>Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomography before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Undergo optical coherence tomography</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
    <other_name>OCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Undergo portable spirometry</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Complete survey</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Digital Photography</intervention_name>
    <description>Undergo digital photography</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Review of medical charts</description>
    <arm_group_label>Observational (sample collection, survey, imaging, spirometry)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tissue, saliva, tears, buccal mucosa, feces
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for allogeneic hematopoietic cell transplantation (HCT) from any donor
        for any indication, with a risk of cGVHD of &gt; 25%
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 18 or older

          -  Scheduled for allogeneic HCT from any donor for any indication, with a risk of cGVHD
             of &gt;25% (see below in exclusion criteria for treatment plans with a cGVHD risk &lt;25%).

          -  Ability and willingness to comply with the intensive assessment schedule including
             evaluation every other month at a participating site.

          -  Ability to communicate in English, to allow completion of patient surveys and clear
             communication with the study team.

        Exclusion Criteria:

          -  Receipt of umbilical cord blood, bone marrow with post-transplant cyclophosphamide
             (peripheral blood with post-transplant cyclophosphamide is allowed), anti-thymocyte
             globulin, alemtuzumab, or ex-vivo T-cell depletion. These patients are excluded
             because they have a cGVHD risk of &lt;25%.

          -  Hematologic malignancy with active disease at the time of transplant. Minimal residual
             disease is allowed.

          -  Hematopoietic cell transplant co-morbidity index &gt; 4 based on parameters known at time
             of enrollment.

          -  Prior allogeneic transplant.

          -  Prior autoimmune disease with ongoing symptoms

          -  History of noncompliance.

          -  Inability to comply with study requirements due to geographic, logistic, social or any
             other factors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcie Hall</last_name>
    <phone>206-667-7010</phone>
    <email>amhall@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Pidala</last_name>
      <phone>813-745-2556</phone>
      <email>joseph.pidala@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Pidala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Pavletic</last_name>
      <phone>240-760-6174</phone>
      <email>pavletis@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Steven Pavletic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Chen</last_name>
      <phone>716-845-8722</phone>
      <email>George.chen@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>George Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Hamilton</last_name>
      <phone>216-445-7580</phone>
      <email>hamiltb2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Betty Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Kitko</last_name>
      <phone>615-936-1762</phone>
      <email>carrie.l.kitko@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Carrie Kitko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcie Hall</last_name>
      <phone>206-667-7010</phone>
      <email>amhall@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

